Cargando…

Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model

BACKGROUND AND OBJECTIVE: In Germany, influenza vaccination is mainly advised for persons aged 60 years and over and individuals with health risks. Since 2021, an inactivated, quadrivalent high-dose influenza vaccine (IIV4-HD) has been recommended for persons aged 60 years and over. The aim of this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pahmeier, Kathrin, Speckemeier, Christian, Neusser, Silke, Wasem, Jürgen, Biermann-Stallwitz, Janine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570167/ https://www.ncbi.nlm.nih.gov/pubmed/37434014 http://dx.doi.org/10.1007/s40273-023-01299-y

Ejemplares similares

Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial
por: Pepin, Stephanie, et al.
Publicado: (2021)

One-year follow-up healthcare costs of patients diagnosed with skin cancer in Germany: a claims data analysis
por: Speckemeier, Christian, et al.
Publicado: (2022)

Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial”
por: Hadigal, Sanjay, et al.
Publicado: (2022)

Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
por: Nham, Eliel, et al.
Publicado: (2023)

1168. Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
por: Nham, Eliel, et al.
Publicado: (2023)

An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population
por: Fochesato, Anna, et al.
Publicado: (2022)

Discrete choice experiment to determine preferences of decision-makers in healthcare for different formats of rapid reviews
por: Speckemeier, Christian, et al.
Publicado: (2021)

Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay
por: Arbo, Antonio, et al.
Publicado: (2022)

Cost-Effectiveness of Vaccination of Older Adults with an MF59(®)-Adjuvanted Quadrivalent Influenza Vaccine Compared to Standard-Dose and High-Dose Vaccines in Denmark, Norway, and Sweden
por: Jacob, Jorge, et al.
Publicado: (2023)

Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2022)

Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination
por: Joshi, Smita, et al.
Publicado: (2023)

Introduction of a quadrivalent influenza vaccine in Italy: a budget impact analysis
por: Pitrelli, A.
Publicado: (2016)

Problems and Barriers Related to the Use of Digital Health Applications: Protocol for a Scoping Review
por: Giebel, Godwin Denk, et al.
Publicado: (2022)

Cost-effectiveness for high dose quadrivalent versus the adjuvanted quadrivalent influenza vaccine in the Italian older adult population
por: Rumi, Filippo, et al.
Publicado: (2023)

Immunogenicity and Safety of One versus Two Doses of Quadrivalent Inactivated Influenza Vaccine (IIV4) in Vaccine-Unprimed Children and One Dose of IIV4 in Vaccine-Primed Children Aged 3–8 Years
por: Shi, Yunfeng, et al.
Publicado: (2023)

Enhanced passive safety surveillance of high‐dose and standard‐dose quadrivalent inactivated split‐virion influenza vaccines in Germany and Finland during the influenza season 2021/22
por: Gandhi‐Banga, Sonja, et al.
Publicado: (2022)

1059 Expanded immunogenicity of high-dose inactivated influenza vaccine compared to standard-dose inactivated influenza vaccine in older adults
por: Diazgranados, Carlos, et al.
Publicado: (2014)

Evaluation of determinants of the serological response to the quadrivalent split‐inactivated influenza vaccine
por: Wu, Shaohuan, et al.
Publicado: (2022)

Problems and Barriers Related to the Use of Digital Health Applications: Scoping Review
por: Giebel, Godwin Denk, et al.
Publicado: (2023)

Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve Children
por: Claeys, Carine, et al.
Publicado: (2019)

Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity
por: Brady, Allison M., et al.
Publicado: (2020)

Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States
por: Krishnarajah, Girishanthy, et al.
Publicado: (2021)

Feasibility of randomizing Danish citizens aged 65–79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 Trial
por: Johansen, Niklas Dyrby, et al.
Publicado: (2022)

Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial
por: Jain, Varsha K., et al.
Publicado: (2017)

High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors
por: Becker, Debbie L., et al.
Publicado: (2016)

Quality Assessment of Digital Health Applications: Protocol for a Scoping Review
por: Giebel, Godwin Denk, et al.
Publicado: (2022)

The rationale for quadrivalent influenza vaccines
por: Ambrose, Christopher S., et al.
Publicado: (2012)

Budget constraint and vaccine dosing: a mathematical modelling exercise
por: Standaert, Baudouin A, et al.
Publicado: (2014)

Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax(®) Tetra/Flucelvax Quadrivalent(®)): A Review in the Prevention of Influenza
por: Lamb, Yvette N.
Publicado: (2019)

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2023)

Quality of life of patients with coronary heart disease treated with the bioresorbable vascular scaffold (ABSORB™): 2-year results from the GABI-R-registry
por: Pahmeier, Kathrin, et al.
Publicado: (2022)

Sex-specific differences of humoral immunity and transcriptome diversification in older adults vaccinated with inactivated quadrivalent influenza vaccines
por: Yang, Jing, et al.
Publicado: (2021)

Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews
por: Carregaro, Rodrigo Luiz, et al.
Publicado: (2023)

Fractional-dose inactivated poliovirus vaccine, India
por: Haldar, Pradeep, et al.
Publicado: (2019)

Correction to: Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax(®) Tetra/Flucelvax Quadrivalent(®)): A Review in the Prevention of Influenza
por: Lamb, Yvette N.
Publicado: (2019)

Assessment of potential public health impact of a quadrivalent inactivated influenza vaccine in Thailand
por: Kittikraisak, Wanitchaya, et al.
Publicado: (2016)

Immunogenicity of Split Inactivated Quadrivalent Influenza Vaccine in Adults with Obesity in the 2017/2018 Season
por: Jagielska, Anna M., et al.
Publicado: (2021)

Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population
por: Tavares, Diana, et al.
Publicado: (2022)

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
por: Kohli, Michele A., et al.
Publicado: (2022)

Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later – an exploratory study
por: Gilca, Vladimir, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c374tcapk5lq6ibhk0mee1mt37